Low-thrombogenic fibrin-heparin coating promotes in vitro endothelialization
Ondřej Kaplan
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Both authors contributed equally to this work.
Search for more papers by this authorTeresa Hierlemann
Department of Thoracic, Cardiac and Vascular Surgery, Clinical Research Laboratory, University Hospital Tuebingen, Tuebingen, DE-72076 Germany
Both authors contributed equally to this work.
Search for more papers by this authorStefanie Krajewski
Department of Thoracic, Cardiac and Vascular Surgery, Clinical Research Laboratory, University Hospital Tuebingen, Tuebingen, DE-72076 Germany
Search for more papers by this authorJulia Kurz
Department of Thoracic, Cardiac and Vascular Surgery, Clinical Research Laboratory, University Hospital Tuebingen, Tuebingen, DE-72076 Germany
Search for more papers by this authorMartina Nevoralová
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Search for more papers by this authorMilan Houska
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Search for more papers by this authorTomáš Riedel
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Search for more papers by this authorZuzana Riedelová
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Search for more papers by this authorJana Zárubová
Institute of Physiology of the Czech Academy of Sciences, Prague, CZ-142 20 Czech Republic
Search for more papers by this authorHans P. Wendel
Department of Thoracic, Cardiac and Vascular Surgery, Clinical Research Laboratory, University Hospital Tuebingen, Tuebingen, DE-72076 Germany
Search for more papers by this authorCorresponding Author
Eduard Brynda
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Correspondence to: Eduard Brynda; e-mail: [email protected]Search for more papers by this authorOndřej Kaplan
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Both authors contributed equally to this work.
Search for more papers by this authorTeresa Hierlemann
Department of Thoracic, Cardiac and Vascular Surgery, Clinical Research Laboratory, University Hospital Tuebingen, Tuebingen, DE-72076 Germany
Both authors contributed equally to this work.
Search for more papers by this authorStefanie Krajewski
Department of Thoracic, Cardiac and Vascular Surgery, Clinical Research Laboratory, University Hospital Tuebingen, Tuebingen, DE-72076 Germany
Search for more papers by this authorJulia Kurz
Department of Thoracic, Cardiac and Vascular Surgery, Clinical Research Laboratory, University Hospital Tuebingen, Tuebingen, DE-72076 Germany
Search for more papers by this authorMartina Nevoralová
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Search for more papers by this authorMilan Houska
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Search for more papers by this authorTomáš Riedel
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Search for more papers by this authorZuzana Riedelová
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Search for more papers by this authorJana Zárubová
Institute of Physiology of the Czech Academy of Sciences, Prague, CZ-142 20 Czech Republic
Search for more papers by this authorHans P. Wendel
Department of Thoracic, Cardiac and Vascular Surgery, Clinical Research Laboratory, University Hospital Tuebingen, Tuebingen, DE-72076 Germany
Search for more papers by this authorCorresponding Author
Eduard Brynda
Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Prague, CZ-162 06 Czech Republic
Correspondence to: Eduard Brynda; e-mail: [email protected]Search for more papers by this authorAbstract
Long-term performance of implanted cardiovascular grafts can be ensured if living endothelium overgrows their surface. Surface modifications to implants are therefore being sought that can encourage endothelialization while preventing thrombus formation until the natural endothelium is formed. In the present study, heparin was covalently attached to a fibrin mesh grown from a polyvinyl chloride (PVC) substrate surface by the catalytic action of surface immobilized thrombin on a fibrinogen solution. The coating prevented platelet activation, thrombin generation and clot formation, and reduced inflammatory reactions when exposed to fresh human whole blood circulating in a Chandler loop model. In addition, in vitro seeded human umbilical vein and human saphenous vein endothelial cells showed considerably enhanced attachment and proliferation on the coating. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 2995–3005, 2017.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Description |
|---|---|
| jbma36152-sup-0001-suppinfo.docx41.6 KB | Supporting Information. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Teebken OE, Haverich A. Tissue engineering of small diameter vascular grafts. Eur J Vasc Endovasc Surg 2002; 23: 475–485.
- 2Kapadia MR, Popowich DA, Kibbe MR. Modified prosthetic vascular conduits. Circulation 2008; 117: 1873–1882.
- 3Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: Roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004; 25: 5681–5703.
- 4Ratner BD. The blood compatibility catastrophe. J Biomed Mater Res 1993; 27: 283–287.
- 5Ratner BD. The catastrophe revisited: Blood compatibility in the 21st Century. Biomaterials 2007; 28: 5144–5147.
- 6Brynda E, Houska M, Jirouskova M, Dyr JE. Albumin and heparin multilayer coatings for blood-contacting medical devices. J Biomed Mater Res 2000; 51: 249–257.
10.1002/(SICI)1097-4636(200008)51:2<249::AID-JBM14>3.0.CO;2-X CAS PubMed Web of Science® Google Scholar
- 7Lavery KS, Rhodes C, Mcgraw A, Eppihimer MJ. Anti-thrombotic technologies for medical devices. Adv Drug Deliv Rev 2017; 112: 2–11.
- 8Ravi S, Chaikof EL. Biomaterials for vascular tissue engineering. Regen Med 2010; 5: 107–120.
- 9Williams SK, Kleinert LB, Patula-Steinbrenner V. Accelerated neovascularization and endothelialization of vascular grafts promoted by covalently bound laminin type 1. J Biomed Mater Res A 2011; 99: 67–73.
- 10Ren XK, Feng YK, Guo JT, Wang HX, Li Q, Yang J, Hao XF, Lv J, Ma N, Li WZ. Surface modification and endothelialization of biomaterials as potential scaffolds for vascular tissue engineering applications. Chem Soc Rev 2015; 15: 5745–5745.
- 11Pang JH, Farhatnia Y, Godarzi F, Tan A, Rajadas J, Cousins BG, Seifalian AM. In situ endothelialization: Bioengineering considerations to translation. Small 2015; 47: 6248–6264.
- 12Ahmed TA, Dare EV, Hincke M. Fibrin: a versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev 2008; 14: 199–215.
- 13Whelan D, Caplice NM, Clover AJP. Fibrin as a delivery system in wound healing tissue engineering applications. J Control Release 2014; 196: 1–8.
- 14Kumar TR, Krishnan LK. A stable matrix for generation of tissue-engineered nonthrombogenic vascular grafts. Tissue Eng 2002; 8: 763–770.
- 15Meinhart JG, Deutsch M, Fischlein T, Howanietz N, Fröschl A, Zilla P. Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts. Ann Thorac Surg 2001; 71: S327–S331.
- 16Riedel T, Brynda E, Dyr JE, Houska M. Controlled preparation of thin fibrin films immobilized at solid surfaces. J Biomed Mater Res A 2009; 88: 437–447.
- 17Riedelova-Reicheltova Z, Brynda E, Riedel T. Fibrin nanostructures for biomedical applications. Physiol Res 2016; 65: S263–S272.
- 18Prowse CV, Korte D, Hess JR, Meer PF. Commercially available blood storage containers. Vox Sang 2014; 106: 1–13.
- 19Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385–391.
- 20Keuren JF, Wielders SJ, Driessen A, Verhoeven M, Hendriks M, Lindhout T. Covalently-bound heparin makes collagen thromboresistant. Arterioscler Thromb Vasc Biol 2004; 24: 613–617.
- 21Hermanson GT. Bioconjugate Techniques, 2nd ed, Rockford: Elsevier; 2008.
- 22Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomat Med Dev Art Org 1983; 11: 161–173.
- 23Krajewski S, Neumann B, Kurz J, Perle N, Avci-Adali M, Cattaneo G, Wendel HP. Preclinical evaluation of the thrombogenicity and endothelialization of bare metal and surface-coated neurovascular stents. Am J Neuroradiol 2015; 36: 133–139.
- 24Krajewski S, Prucek R, Panacek A, Avci-Adali M, Nolte A, Straub A, Zboril R, Wendel HP, Kvitek L. Hemocompatibility evaluation of different silver nanoparticle concentrations employing a modified Chandler-loop in vitro assay on human blood. Acta Biomater 2013; 9: 7460–7468.
- 25Avci-Adali M, Kobba J, Neumann B, Lescan M, Perle N, Wilhelm N, Wiedmaier H, Schlensak C, Wendel HP. Application of a rotating bioreactor consisting of low-cost and ready-to-use medical disposables for in vitro evaluation of the endothelialization efficiency of small-caliber vascular prostheses. J Biomed Mater Res B Appl Biomater 2013; 101: 1061–1068.
- 26Gore S, Andersson J, Biran R, Underwood C, Riesenfeld J. Heparin surfaces: Impact of immobilization chemistry on hemocompatibility and protein adsorption. J Biomed Mater Res B 2014; 102B: 1817–1824.
- 27Hoshi RA, Lith RV, Jen MC, Allen JB, Lapidos KA, Ameer G. The blood and vascular cell compatibility of heparin-modified ePTFE vascular grafts. Biomaterials 2013; 34: 30–41.
- 28Ding YH, Yang M, Yang ZL, Luo RF, Lu X, Huang N, Huang PB, Leng Y. Cooperative control of blood compatibility and re-endothelialization by immobilized heparin and substrate topography. Acta Biomaterialia 2015; 15: 150–163.
- 29Yang ZL, Wang J, Luo RF, Maitz MF, Jing FJ, Sun H, Huang N. The covalent immobilization of heparin to pulsed-plasma polymeric allylamine films on 316L stainless steel and the resulting effects on hemocompatibility. Biomaterials 2010; 31: 2072–2083.
- 30Filova E, Brynda E, Riedel T, Bacakova L, Chlupac J, Lisa V, Houska M, Dyr JE. Vascular endothelial cells on two-and three-dimensional fibrin assemblies for biomaterial coatings. J Biomed Mater Res A 2009; 90: 55–69.
- 31Filova E, Brynda E, Riedel T, Chlupac J, Vandrovcova M, Svindrych Z, Lisa V, Houska M, Pirk J, Bacakova L. Improved adhesion and differentiation of endothelial cells on surface-attached fibrin structures containing extracellular matrix proteins. J Biomed Mater Res A 2014; 102: 698–712.
- 32Chlupac J, Filova E, Riedel T, Houska M, Brynda E, Remy-Zolghadri M, Bareille R, Fernandez P, Daculsi R, Bourget C, Bordenave L, Bacakova L. Attachment of human endothelial cells to polyester vascular grafts: pre-coating with adhesive protein assemblies and resistance to short-term shear stress. Physiol Res 2014; 63: 167–177.
- 33Yang Z, Tu Q, Wang J, Huang N. The role of heparin binding surfaces in the direction of endothelial and smooth muscle cell fate and re-endothelialization. Biomaterials 2012; 33: 6615–6625.
- 34Lu Y, Shen L, Gong F, Cui J, Rao J, Chen J, Yang W. Polycarbonate urethane films modified by heparin to enhance hemocompatibility and endothelialization. Polymer Int 2012; 61: 1433–1438.
- 35Melchiorri AJ, Hibino N, Yi T, Lee YU, Sugiura T, Tara S, Shinoka T, Breuer C, Fisher JP. Contrasting biofunctionalization strategies for the enhanced endothelialization of biodegradable vascular grafts. Biomacromolecules 2015; 16: 437–446.
- 36Jeon O, Soo HR, Ji HC, Kim BS. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J Control Release 2005; 105: 249–259.
- 37Han H, Ao Q, Chen G, Wang S, Zuo H. A novel basic fibroblast growth factor delivery system fabricated with heparin-incorporated fibrin–fibronectin matrices for repairing rat sciatic nerve disruptions. Biotechnol Lett 2010; 32: 585–591.
- 38Yang HS, Bhang SH, Hwang JW, Kim DI, Kim BS. Delivery of basic fibroblast growth factor using heparin-conjugated fibrin for therapeutic angiogenesis. Tissue Eng Part A 2010; 16: 2113–2119.
Citing Literature
